Lantern Pharma’s WithZeta AI Is Accelerating the Future of Cancer Drug Discovery

A new era in cancer research is here. Lantern Pharma (NASDAQ: LTRN) has introduced WithZeta, an advanced artificial intelligence platform designed to accelerate the discovery and development of treatments for rare and hard-to-treat cancers. By analyzing vast biological datasets, the platform helps identify promising drug candidates, predict clinical outcomes, and streamline the development process.

WithZeta is built to reduce the time, cost, and uncertainty associated with oncology drug development, giving researchers powerful AI-driven tools to advance precision medicine and bring innovative cancer therapies to patients faster. Learn more about Lantern Pharma and its AI-powered approach to cancer drug discovery through New to the Street.

#LanternPharma
#LTRN
#WithZeta
#ArtificialIntelligence
#AI
#CancerResearch
#DrugDiscovery
#PrecisionMedicine
#Biotechnology
#Oncology
#HealthcareInnovation
#ClinicalDevelopment
#NASDAQ
#NewToTheStreet
#NewsOut